- 1.
Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol 2011; 90: 1191–200. [PubMed][CrossRef]
- 2.
Grundtvig J, Ovesen C, Havsteen I et al. Trends in incidence of oral anticoagulant-related intracerebral hemorrhage and sales of oral anticoagulants in Capital Region of Denmark 2010-2017. Eur Stroke J 2021; 6: 143–50. [PubMed][CrossRef]
- 3.
Steiner T, Weitz JI, Veltkamp R. Anticoagulant-associated intracranial hemorrhage in the era of reversal agents. Stroke 2017; 48: 1432–7. [PubMed][CrossRef]
- 4.
Gulati S, Solheim O, Carlsen SM et al. Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study. PLoS One 2018; 13: e0202575. [PubMed][CrossRef]
- 5.
Kjerpeseth LJ, Igland J, Selmer R et al. Prevalence and incidence rates of atrial fibrillation in Norway 2004-2014. Heart 2021; 107: 201–7. [PubMed][CrossRef]
- 6.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–8. [PubMed][CrossRef]
- 7.
Christensen H, Cordonnier C, Kõrv J et al. European Stroke Organisation Guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage. Eur Stroke J 2019; 4: 294–306. [PubMed][CrossRef]
- 8.
Berg CL, Olsen K, Sakshaug S. Reseptregisteret 2014–2018. Legemiddelstatistikk 2019:2. Oslo: Folkehelseinstitutet, 2019. https://www.fhi.no/contentassets/4df2902e8492453bb22c219bf69d8f71/191303_legemiddelstatistikk2019.pdf Lest 30.5.2021.
- 9.
Fjærtoft H, Skogseth-Stephani R, Indredavik B et al. Norsk hjerneslagsregister. Årsrapport 2019. Trondheim: St. Olavs hospital, 2019. https://www.kvalitetsregistre.no/sites/default/files/1_arsrapport_2019_norsk_hjerneslagregister_justert_21.10.2020.pdf Lest 30.5.2021.
- 10.
Ovesen C, Christensen AF, Krieger DW et al. Time course of early postadmission hematoma expansion in spontaneous intracerebral hemorrhage. Stroke 2014; 45: 994–9. [PubMed][CrossRef]
- 11.
Hemphill JC, Greenberg SM, Anderson CS et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015; 46: 2032–60. [PubMed][CrossRef]
- 12.
Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010; 8: 149–54. [PubMed]
- 13.
Steiner T, Poli S, Griebe M et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 2016; 15: 566–73. [PubMed][CrossRef]
- 14.
Sarode R, Milling TJ, Refaai MA et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128: 1234–43. [PubMed][CrossRef]
- 15.
Yasaka M, Sakata T, Minematsu K et al. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2002; 108: 25–30. [PubMed][CrossRef]
- 16.
Pollack CV, Reilly PA, Eikelboom J et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373: 511–20. [PubMed][CrossRef]
- 17.
Connolly SJ, Crowther M, Eikelboom JW et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380: 1326–35. [PubMed][CrossRef]
- 18.
Gerner ST, Kuramatsu JB, Sembill JA et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol 2018; 83: 186–96. [PubMed][CrossRef]
- 19.
Purrucker JC, Haas K, Rizos T et al. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurol 2016; 73: 169–77. [PubMed][CrossRef]
- 20.
Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573–9. [PubMed][CrossRef]
- 21.
Cheung YW, Barco S, Hutten BA et al. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J Thromb Haemost 2015; 13: 1799–805. [PubMed][CrossRef]
- 22.
Zahir H, Brown KS, Vandell AG et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131: 82–90. [PubMed][CrossRef]
- 23.
Lazo-Langner A, Lang ES, Douketis J. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. Crit Care 2013; 17: 230. [PubMed][CrossRef]
- 24.
Gatt A, van Veen JJ, Woolley AM et al. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008; 100: 350–5. [PubMed][CrossRef]
- 25.
Harenberg J, Siegele M, Dempfle CE et al. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins. Thromb Haemost 1993; 70: 942–5. [PubMed][CrossRef]
- 26.
Frontera JA, Lewin JJ, Rabinstein AA et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: A statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016; 24: 6–46. [PubMed][CrossRef]
- 27.
Parkin TW, Kvale WF. Neutralization of the anticoagulant effects of heparin with protamine (salmine). Am Heart J 1949; 37: 333–42. [PubMed][CrossRef]
- 28.
Paroutoglou K, Parry-Jones AR. Hyperacute management of intracerebral haemorrhage. Clin Med (Lond) 2018; 18 (suppl 2): s9–12. [PubMed][CrossRef]
- 29.
Sandset EC, Anderson CS, Bath PM et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. Eur Stroke J 2021; 6: 23969873211012133. [CrossRef]
- 30.
Al-Shahi Salman R, Frantzias J, Lee RJ et al. Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Lancet Neurol 2018; 17: 885–94. [PubMed][CrossRef]
- 31.
Kuramatsu JB, Gerner ST, Schellinger PD et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313: 824–36. [PubMed][CrossRef]
()
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.